Skip to main content

Table 1 Study schedule

From: The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial

  1. ICDRG International Contact Dermatitis Research Group
Back to article page

Trials

ISSN: 1745-6215